Status:
COMPLETED
Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
3-17 years
Phase:
PHASE3
Brief Summary
The primary objective is to assess the safety, efficacy and tolerability of the combination of PEG-Intron plus REBETOL in pediatric subjects with chronic hepatitis C. The secondary objective is to mea...
Detailed Description
This global, multicenter, open-label Phase 3 study will evaluate the safety, efficacy and tolerability of PEG-Intron plus REBETOL in previously untreated pediatric subjects, ages 3 through 17 years, w...
Eligibility Criteria
Inclusion
- Children age 3-17 years old
- Individuals weighing ≤ 90 kg
- Previously untreated children with chronic hepatitis C (HCV RNA qPCR plasma positive)
- Individuals with any HCV (hepatitis C virus) genotype
- Hematology laboratory results of:
- Hemoglobin (HGB) ≥ 11 g/dL for females or ≥ 12g/dL for males,
- White Blood Cell Count (WBC) ≥ 3,000/mm\^3,
- Neutrophils ≥ 1,500/mm\^3,
- Platelets ≥ 100,000/mm\^3
- Chemistry laboratory results of:
- Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and Bilirubin,
- Antinuclear antibody (ANA) ≤ 1:160,
- Fasting Glucose 70-140 mg/dL. Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, HbA1C must be ≤ 8.5%
- Compensated liver disease
- Historic or pre-treatment liver biopsy slides available
- No significant co-existing psychiatric disease
- Those with diabetes, hypertension, or birth prior to 32 weeks gestational age must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)
- Patients and partners of patients willing to use adequate contraception during the course of the study
- Abstain from alcohol and any other illicit drugs
Exclusion
- Serum ALT \>10 times the upper limit of normal within the 6 months prior to study
- Previous hepatitis C treatment
- Children with liver disease not caused by hepatitis C
- Most recent liver biopsy is normal
- Individuals infected with the hepatitis B virus and/or human immunodeficiency virus (HIV)
- Known blood disorders such as hemoglobinopathy, coagulopathy, or G6PD deficiency
- Known immunodeficiency disorders requiring immunoglobulin therapy
- Body organ transplant
- Any known or suspected cancer within the past 5 years
- Children with chronic pulmonary disease
- Individuals who have a medical condition that would likely require systemic steroids
- Those with a history of central nervous system (CNS) trauma or seizure disorders
- Individuals with pre-existing psychiatric disorders including but not limited to moderate to severe depression
- Current or previous use of lithium or antipsychotic drugs
- Patients with clinically significant electrocardiogram (ECG) abnormalities and/or significant cardiovascular dysfunction (e.g., angina, congestive heart failure, recent myocardial infarction, uncontrolled hypertension, significant arrhythmia, cardiac sequelae from Kawasaki disease, cardiomyopathy, and/or history of congenital heart disease)
- Insulin-dependent diabetes mellitus or poorly controlled non-insulin dependent diabetes mellitus
- Immunologically mediated disease (e.g., inflammatory bowel disease \[Crohn's disease, ulcerative colitis\], rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, or symptomatic thyroid disorder)
- History of substance abuse, including alcohol (e.g., binge drinking, blackouts), intravenous drugs and inhaled drugs
- Subjects who have a history of pregnancy or who are pregnant and/or breast feeding. Subjects who intend to become pregnant during the study period. Subjects with partners who intend to become pregnant during the study period
- Subjects with clinically significant retinal abnormalities such as known retinopathy of prematurity or other retinopathies
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT00104052
Start Date
February 1 2005
End Date
November 1 2007
Last Update
April 4 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.